Human Genome Sciences, Inc. (Nasdaq:HGSI) and Lonza announced an agreement for the future commercial supply of BENLYSTAŽ (belimumab), which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE)...

More...